DEUTSCHE BANK AG\ - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 84 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$898,445
+116.0%
30,210
+30.9%
0.00%
Q2 2023$415,992
-32.4%
23,085
-39.8%
0.00%
Q1 2023$615,403
+14.9%
38,319
+31.0%
0.00%
Q4 2022$535,404
+26.6%
29,257
+35.9%
0.00%
Q3 2022$423,000
-9.2%
21,521
-13.8%
0.00%
Q2 2022$466,000
-19.2%
24,963
-5.1%
0.00%
Q1 2022$577,000
-30.6%
26,293
-10.2%
0.00%
Q4 2021$832,000
-56.1%
29,271
-67.5%
0.00%
-100.0%
Q3 2021$1,896,000
+12.9%
90,056
+1.1%
0.00%0.0%
Q2 2021$1,679,000
+29.4%
89,086
+4.8%
0.00%0.0%
Q1 2021$1,298,000
+349.1%
84,966
+315.1%
0.00%
Q4 2020$289,000
+19.4%
20,471
+32.7%
0.00%
Q3 2020$242,000
-2.0%
15,427
+9.2%
0.00%
Q2 2020$247,000
+341.1%
14,121
+271.8%
0.00%
Q1 2020$56,000
-44.0%
3,798
-5.5%
0.00%
Q4 2019$100,000
+122.2%
4,020
+29.6%
0.00%
Q3 2019$45,000
-44.4%
3,101
-5.4%
0.00%
Q2 2019$81,000
-61.4%
3,278
-64.9%
0.00%
Q1 2019$210,000
+3.4%
9,346
+36.5%
0.00%
Q4 2018$203,000
-76.1%
6,846
-76.9%
0.00%
Q3 2018$848,00029,6830.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders